An Investigational Vaccine in Reducing the Incidence of Anogenital Warts in Young Men.

Trial Profile

An Investigational Vaccine in Reducing the Incidence of Anogenital Warts in Young Men.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Anal cancer; Anal intraepithelial neoplasia; Genital warts; Human papillomavirus infections; Penile cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 11 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 26 Mar 2017 This trial has been completed in Spain.
    • 11 Apr 2016 Planned End Date changed from 1 Dec 2017 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top